David Willman is a Pulitzer Prize winning investigative journalist. His work has prompted major public reforms, including a ban in 2005 of drug company payments to government scientists at the U.S. National Institutes of Health. Willman’s investigative reports in the Los Angeles Times also led to the March 2000 safety withdrawal of Rezulin, a Type 2 Diabetes drug that grossed more than $2 billion in sales.
In awarding Willman the Pulitzer Prize (...
more
David Willman is a Pulitzer Prize winning investigative journalist. His work has prompted major public reforms, including a ban in 2005 of drug company payments to government scientists at the U.S. National Institutes of Health. Willman’s investigative reports in the Los Angeles Times also led to the March 2000 safety withdrawal of Rezulin, a Type 2 Diabetes drug that grossed more than $2 billion in sales.
In awarding Willman the Pulitzer Prize (
http://www.pulitzer.org/year/2001/investigative-reporting/bio/) for investigative reporting in 2001, the organization cited ``his pioneering expose of seven unsafe prescription drugs that had been approved by the Food and Drug Administration, and an analysis of the policy reforms that had reduced the agency’s effectiveness.’’
In 2004, Willman won the Worth Bingham Prize, awarded for ``investigative reporting of stories of national significance where the public interest is ill-served.’’ Willman had brought to light drug company payments...
less
